What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addr...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	McGovern, A, Dennis, J, Shields, B, Hattersley, A, Pearson, E, Jones, A, Mastermind Consortium
Andre forfattere:	Farmer, A
Format:	Journal article
Sprog:	English
Udgivet:	BioMed Central 2019

Lignende værker

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
af: Andrew P. McGovern, et al.
Udgivet: (2019-04-01)

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
af: Angus G Jones, et al.
Udgivet: (2016-01-01)

Costs and treatment pathways for type 2 diabetes in the UK: a Mastermind Cohort study
af: Eibich, U, et al.
Udgivet: (2017)

Mastermind ophthalmology
af: Madhav
Udgivet: (2007-01-01)

Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
af: Agbaje, O, et al.
Udgivet: (2017)

Fructosamine and HbA1c
af: Kurumbian Chandran, et al.
Udgivet: (2024-02-01)

Oliver heaviside : maverick mastermind of electricity /
af: 309384 Mahon, Basil
Udgivet: (2009)

Use of HbA1c in the diagnosis of diabetes.
af: Farmer, A
Udgivet: (2012)

Artifactually lowered glycosylated hemoglobin (HbA1c %) in patient with diabetes on dapsone
af: Amit Rastogi, et al.
Udgivet: (2012-01-01)

What are the HbA(1c) thresholds for initiating insulin therapy in people with type 2 diabetes in UK primary care?
af: Hinton, W, et al.
Udgivet: (2016)

Predictors of HbA1c treatment response to add-on medication following metformin monotherapy: a population-based cohort study
af: Wei Ying Tan, et al.
Udgivet: (2023-11-01)

HbA1C and diabetes – an overview
af: S Pathmanathan, et al.
Udgivet: (2014-01-01)

A new 6.111 laboratory exercise : Mastermind
af: Mahn, Nathan A. (Nathan Aaron), 1979-
Udgivet: (2014)

High-performance liquid chromatography local reference ranges of hemoglobin fractions (HbA, HbA2, and HbF) in detection of hemoglobinopathies in western Kenya
af: Benard Mutua, et al.
Udgivet: (2022-12-01)

The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables.
af: Marcus Lind, et al.
Udgivet: (2009-01-01)

Epstein-Barr virus: the mastermind of immune chaos
af: Jean de Melo Silva, et al.
Udgivet: (2024-02-01)

The Exact Query Complexity of Yes-No Permutation Mastermind
af: Mourad El Ouali, et al.
Udgivet: (2020-04-01)

Mumbai Investigation: The Operatives, Masterminds and Enduring Threat
af: Rohan Gunaratna
Udgivet: (2009-01-01)

Selective Phenotyping, Entropy Reduction, and the Mastermind game
af: Gagneur Julien, et al.
Udgivet: (2011-10-01)

The Paradox of Help Seeking in the Entropy Mastermind Game
af: Nichola Taylor, et al.
Udgivet: (2020-09-01)

Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
af: Schmidt, W, et al.
Udgivet: (2009)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
af: Xiaojing Feng, et al.
Udgivet: (2021-05-01)

Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)
af: Gough, S, et al.
Udgivet: (2010)

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
af: Mostafa, SA, et al.
Udgivet: (2017)

Effects of thyroid status on HbA1c
af: Sivaranjani Ambalavanan, et al.
Udgivet: (2024-11-01)

Drugs affecting HbA1c levels
af: Ranjit Unnikrishnan, et al.
Udgivet: (2012-01-01)

Current Status of HbA1c Biosensors
af: Hua Lin, et al.
Udgivet: (2017-08-01)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements.
af: Nasir, N.M., et al.
Udgivet: (2010)

Sleep characteristics and HbA1c in patients with type 2 diabetes on glucose-lowering medication
af: Christian Benedict
Udgivet: (2020-04-01)

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
af: Kurukulasuriya L Romayne, et al.
Udgivet: (2010-08-01)

Death of Bahrun Naim : Mastermind of Terror in Southeast Asia
af: Gunaratna, Rohan
Udgivet: (2018)

“Evil Mastermind” in the framework of a verbally modeled reality
af: Oleksandr Kolesnyk, et al.
Udgivet: (2022-12-01)

Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study
af: Lauren R. Rodgers, et al.
Udgivet: (2021-08-01)

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
af: Katherine G. Young, et al.
Udgivet: (2023-11-01)

Glycated haemoglobin - when can we trust it? Analysis of factors affecting the HbA1c level
af: Marcin Lewicki, et al.
Udgivet: (2018-12-01)

Glycated haemoglobin - when can we trust it? Analysis of factors affecting the HbA1c level
af: Marcin Lewicki, et al.
Udgivet: (2018-12-01)

Haemoglobin types and variant interference with HbA1c and its association with uncontrolled HbA1c in type 2 diabetes mellitus
af: Joseph Malaba, et al.
Udgivet: (2024-11-01)

Symposium 3: HbA1c: Are HbA1c determinations reliable enough today in Argentina to adopt them as diagnostic criteria?
af: Carla Lucarelli
Udgivet: (2022-09-01)

Understanding the relationship between the frequency of HbA1c monitoring, HbA1c changes over time, and the achievement of targets: a retrospective cohort study
af: Elton Mukonda, et al.
Udgivet: (2025-01-01)

HbA1c in patients with glioblastomas - a preliminary study
af: D. Orešković, et al.
Udgivet: (2022-01-01)